Media coverage
2Media coverage
Title U.S. FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease Media name/outlet FirstWord Pharma Country United States Date 10/30/18 Persons Ralph A Defronzo Title U.S. FDA Approves INVOKANA (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease Media name/outlet Pharmacy Choice Country United States Date 10/30/18 Persons Ralph A Defronzo